The Medicines and Healthcare products Regulatory Agency has restated that routine childhood vaccination remains safe and that available evidence does not support a link between vaccines and autism. In its public statement, the regulator said vaccination remains one of the most effective protections against serious infectious disease and remains backed by the NHS and major UK public health and paediatric bodies. For policy readers, the immediate point is that the MHRA is not announcing any change to the UK childhood immunisation schedule. The statement functions instead as a formal reaffirmation of the existing evidence base, the current regulatory position and the reporting routes available to parents, carers and clinicians.
On the central claim, the MHRA said multiple large international studies involving millions of children have found no evidence that vaccines cause autism. It referred to national registry studies, sibling-controlled studies and a 2014 meta-analysis published in Vaccine that pooled data from more than 1.26 million children in cohort studies and nearly 10,000 children in case-control studies, again finding no association between vaccination and autism or autism spectrum disorder. The agency also pointed to a 2026 US study covering 2.56 million children, which reported no association between MMR vaccination before age two and autism. On another area that has attracted public concern, the MHRA said a recent large-scale study of aluminium-containing vaccines did not identify evidence of increased risk for neurodevelopmental disorders, including autism. It also noted that aluminium adjuvants are not used in the MMR vaccine.
The statement sets out the regulatory sequence in straightforward terms. Before approval, vaccines used in the UK are assessed by the MHRA for safety, quality and efficacy. That pre-authorisation review is then followed by continuous post-market surveillance once a product is in routine use. According to the MHRA, that surveillance draws on Yellow Card reports, analysis of large healthcare datasets, international safety evidence and review by independent scientific experts. The regulator added that if new evidence were to indicate a change in vaccine safety, it would move to update guidance and public information promptly.
The wider policy framework remains unchanged. The NHS childhood vaccination schedule is informed by evidence-based recommendations from the Joint Committee on Vaccination and Immunisation, with delivery supported by NHS clinical guidance. The MHRA also notes that routine childhood vaccination is recommended by the World Health Organization and by public health authorities internationally as the most effective way to protect children from serious infectious diseases. That matters operationally because the statement is not a standalone communications exercise. It reinforces the current line across the health system that vaccination against conditions such as measles, meningitis and whooping cough should continue in line with the routine schedule unless a clinician advises otherwise.
For parents and carers, the practical message is unchanged. The MHRA is advising families to continue following NHS vaccination guidance and to raise individual questions with a healthcare professional rather than relying on unsupported claims. The agency has also highlighted its vaccine safety patient factsheet and a separate meningitis factsheet designed to explain how vaccine safety is assessed, how meningitis symptoms can present and why prevention matters. These documents sit alongside routine clinical advice and are intended to give the public a clearer route into the evidence and the relevant safety processes.
The reporting mechanism remains the Yellow Card scheme, through which members of the public and healthcare professionals can submit suspected side effects linked to medicines and vaccines. In regulatory terms, those reports support signal detection and further investigation, rather than serving on their own as proof that a vaccine caused a particular event. The MHRA, an executive agency of the Department of Health and Social Care, said patient safety remains its priority and repeated that any future action would be evidence-led. The practical effect of this latest statement is therefore to restate both parts of the current policy position: the routine childhood vaccination programme remains recommended, and the surveillance arrangements around vaccine safety remain active.